Geneuro SA (GNRO) - Total Liabilities
Based on the latest financial reports, Geneuro SA (GNRO) has total liabilities worth €20.14 Million EUR (≈ $23.55 Million USD) as of December 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See GNRO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Geneuro SA - Total Liabilities Trend (2012–2023)
This chart illustrates how Geneuro SA's total liabilities have evolved over time, based on quarterly financial data. Check Geneuro SA liquidity resilience to evaluate the company's liquid asset resilience ratio.
Geneuro SA Competitors by Total Liabilities
The table below lists competitors of Geneuro SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aker Horizons AS
OL:AKH
|
Norway | Nkr21.20 Billion |
|
The Hydration Pharmaceuticals Company Ltd
AU:HPC
|
Australia | AU$1.22 Million |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
Poland | zł2.19 Million |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
Indonesia | Rp942.71 Billion |
|
Teras Resources Inc
V:TRA
|
Canada | CA$932.72K |
|
BEACN Wizardry & Magic Inc
V:BECN
|
Canada | CA$2.17 Million |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
UK | GBX11.69 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Geneuro SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GNRO current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Geneuro SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Geneuro SA (2012–2023)
The table below shows the annual total liabilities of Geneuro SA from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €20.14 Million ≈ $23.55 Million |
+101.26% |
| 2022-12-31 | €10.01 Million ≈ $11.70 Million |
+30.05% |
| 2021-12-31 | €7.69 Million ≈ $9.00 Million |
+54.00% |
| 2020-12-31 | €5.00 Million ≈ $5.84 Million |
-65.80% |
| 2019-12-31 | €14.61 Million ≈ $17.08 Million |
+171811.08% |
| 2018-12-31 | €8.50K ≈ $9.93K |
-50.92% |
| 2017-12-31 | €17.31K ≈ $20.24K |
-9.42% |
| 2016-12-31 | €19.11K ≈ $22.34K |
+0.23% |
| 2015-12-31 | €19.07K ≈ $22.29K |
-99.32% |
| 2014-12-31 | €2.82 Million ≈ $3.29 Million |
+89.33% |
| 2013-12-31 | €1.49 Million ≈ $1.74 Million |
-71.43% |
| 2012-12-31 | €5.21 Million ≈ $6.09 Million |
-- |
About Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more